Osborn Rohs Williams & Donohoe Ltd decreased its stake in Novartis AG (NYSE:NVS) by 4.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 63,970 shares of the company’s stock after selling 2,824 shares during the period. Osborn Rohs Williams & Donohoe Ltd’s holdings in Novartis AG were worth $5,051,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in NVS. Parnassus Investments CA boosted its stake in Novartis AG by 61.3% in the second quarter. Parnassus Investments CA now owns 3,481,896 shares of the company’s stock valued at $287,291,000 after buying an additional 1,323,724 shares during the period. Thomaspartners Inc. boosted its stake in Novartis AG by 76.6% in the second quarter. Thomaspartners Inc. now owns 2,620,677 shares of the company’s stock valued at $216,232,000 after buying an additional 1,136,338 shares during the period. Aristotle Capital Management LLC boosted its stake in Novartis AG by 31.9% in the second quarter. Aristotle Capital Management LLC now owns 2,736,946 shares of the company’s stock valued at $225,825,000 after buying an additional 662,285 shares during the period. FMR LLC boosted its stake in Novartis AG by 65.6% in the second quarter. FMR LLC now owns 1,208,384 shares of the company’s stock valued at $99,704,000 after buying an additional 478,679 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Novartis AG during the second quarter valued at about $37,505,000. 9.86% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Shares of Novartis AG (NYSE:NVS) traded down 0.17% on Tuesday, hitting $68.96. 1,803,283 shares of the stock were exchanged. The firm’s 50 day moving average price is $72.79 and its 200 day moving average price is $78.41. The firm has a market cap of $163.82 billion, a price-to-earnings ratio of 24.32 and a beta of 0.71. Novartis AG has a one year low of $67.28 and a one year high of $88.49.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 25th. The company reported $1.23 EPS for the quarter, beating the Zacks’ consensus estimate of $1.19 by $0.04. Novartis AG had a net margin of 13.98% and a return on equity of 15.25%. The firm had revenue of $12.13 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the firm posted $1.27 EPS. The firm’s revenue was down 1.1% compared to the same quarter last year. Equities analysts anticipate that Novartis AG will post $4.72 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/novartis-ag-nvs-stake-decreased-by-osborn-rohs-williams-donohoe-ltd.html.

NVS has been the subject of a number of research reports. Zacks Investment Research cut shares of Novartis AG from a “hold” rating to a “sell” rating in a research report on Wednesday, September 21st. Jefferies Group reissued a “buy” rating on shares of Novartis AG in a research report on Sunday, October 16th. Chardan Capital reduced their price target on shares of Novartis AG from $95.00 to $92.00 and set a “buy” rating for the company in a research report on Monday, October 10th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis AG in a research report on Tuesday, September 13th. Finally, Argus raised shares of Novartis AG from a “hold” rating to a “buy” rating and set a $85.00 price target for the company in a research report on Thursday, November 10th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $88.50.

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.